<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="research-article" dtd-version="2.3" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">MSJ</journal-id>
<journal-id journal-id-type="hwp">spmsj</journal-id>
<journal-id journal-id-type="nlm-ta">Mult Scler</journal-id>
<journal-title>Multiple Sclerosis Journal</journal-title>
<issn pub-type="ppub">1352-4585</issn>
<issn pub-type="epub">1477-0970</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1352458511431076</article-id>
<article-id pub-id-type="publisher-id">10.1177_1352458511431076</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Research Papers</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Recommendations for a Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS)</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes" xlink:type="simple">
<name name-style="western"><surname>Langdon</surname><given-names>DW</given-names></name>
<xref ref-type="aff" rid="aff1-1352458511431076">1</xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western"><surname>Amato</surname><given-names>MP</given-names></name>
<xref ref-type="aff" rid="aff2-1352458511431076">2</xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western"><surname>Boringa</surname><given-names>J</given-names></name>
<xref ref-type="aff" rid="aff3-1352458511431076">3</xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western"><surname>Brochet</surname><given-names>B</given-names></name>
<xref ref-type="aff" rid="aff4-1352458511431076">4</xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western"><surname>Foley</surname><given-names>F</given-names></name>
<xref ref-type="aff" rid="aff5-1352458511431076">5</xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western"><surname>Fredrikson</surname><given-names>S</given-names></name>
<xref ref-type="aff" rid="aff6-1352458511431076">6</xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western"><surname>Hämäläinen</surname><given-names>P</given-names></name>
<xref ref-type="aff" rid="aff7-1352458511431076">7</xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western"><surname>Hartung</surname><given-names>H-P</given-names></name>
<xref ref-type="aff" rid="aff8-1352458511431076">8</xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western"><surname>Krupp</surname><given-names>L</given-names></name>
<xref ref-type="aff" rid="aff9-1352458511431076">9</xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western"><surname>Penner</surname><given-names>IK</given-names></name>
<xref ref-type="aff" rid="aff10-1352458511431076">10</xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western"><surname>Reder</surname><given-names>AT</given-names></name>
<xref ref-type="aff" rid="aff11-1352458511431076">11</xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western"><surname>Benedict</surname><given-names>RHB</given-names></name>
<xref ref-type="aff" rid="aff12-1352458511431076">12</xref>
</contrib>
</contrib-group>
<aff id="aff1-1352458511431076"><label>1</label>Royal Holloway, University of London, Surrey, UK.</aff>
<aff id="aff2-1352458511431076"><label>2</label>Careggi University Hospital, Florence, Italy.</aff>
<aff id="aff3-1352458511431076"><label>3</label>Meander Medisch Centrum, Amersfoort, The Netherlands.</aff>
<aff id="aff4-1352458511431076"><label>4</label>Universite de Bordeaux, France.</aff>
<aff id="aff5-1352458511431076"><label>5</label>Yeshiva University, Bronx, NY, USA and Holy Name Hospital Multiple Sclerosis Center, Teaneck, NJ, USA.</aff>
<aff id="aff6-1352458511431076"><label>6</label>Karolinska Institute, Huddinge University Hospital, Stockholm, Sweden.</aff>
<aff id="aff7-1352458511431076"><label>7</label>Masku Neurological Rehabilitation Centre, Masku, Finland.</aff>
<aff id="aff8-1352458511431076"><label>8</label>Heinrich-Heine-Universitat, Duesseldorf, Germany.</aff>
<aff id="aff9-1352458511431076"><label>9</label>Albert Einstein College of Medicine New York, USA.</aff>
<aff id="aff10-1352458511431076"><label>10</label>University of Basel, Switzerland.</aff>
<aff id="aff11-1352458511431076"><label>11</label>University of Chicago, USA.</aff>
<aff id="aff12-1352458511431076"><label>12</label>Jacobs Neurological Institute, New York, USA.</aff>
<author-notes>
<corresp id="corresp1-1352458511431076">Professor DW Langdon, Royal Holloway, University of London, Egham, Surrey, TW20 0EX, UK. Email: <email xlink:type="simple">d.langdon@rhul.ac.uk</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>6</month>
<year>2012</year>
</pub-date>
<volume>18</volume>
<issue>6</issue>
<fpage>891</fpage>
<lpage>898</lpage>
<history>
<date date-type="received">
<day>16</day>
<month>10</month>
<year>2011</year>
</date>
<date date-type="accepted">
<day>3</day>
<month>11</month>
<year>2011</year>
</date>
</history>
<permissions>
<copyright-statement>© The Author(s) 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
  <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0/" xlink:type="simple">
    <p>This is an open-access article distributed under the terms of the Creative
      Commons Attribution License, which permits unrestricted use, distribution,
      and reproduction in any medium, provided the original work is properly
      cited.</p>
  </license>
</permissions>
<abstract>
<p><bold>Background:</bold> Cognitive impairment in MS impacts negatively on many patients at all disease stages and in all subtypes. Full clinical cognitive assessment is expensive, requiring expert staff and special equipment. Test versions and normative data are not available for all languages and cultures.</p>
<p><bold>Objective:</bold> To recommend a brief cognitive assessment for multiple sclerosis (MS) that is optimized for small centers, with one or few staff members, who may not have neuropsychological training and constructed to maximize international use.</p>
<p><bold>Methods:</bold> An expert committee of twelve members representing the main cultural groups that have so far contributed considerable data about MS cognitive dysfunction was convened. Following exhaustive literature review, peer-reviewed articles were selected to cover a broad spectrum of cultures and scales that targeted cognitive domains vulnerable to MS. Each was rated by two committee members and candidates scales were rated on psychometric qualities (reliability, validity, and sensitivity), international application, ease of administration, feasibility in the specified context, and acceptability to patients.</p>
<p><bold>Results:</bold> The committee recommended the Symbol Digit Modalities Test, if only 5 minutes was available, with the addition of the California Verbal Learning Test – Second Edition and the Brief Visuospatial Memory Test – Revised learning trials if a further 10 minutes could be allocated for testing.</p>
<p><bold>Conclusions:</bold> A brief cognitive assessment for MS has been recommended. A validation protocol has been prepared for language groups and validation studies have commenced.</p>
</abstract>
<kwd-group>
<kwd>multiple sclerosis</kwd>
<kwd>cognition information processing</kwd>
<kwd>memory</kwd>
<kwd>assessment</kwd>
<kwd>psychometrics</kwd>
<kwd>neuropsychology</kwd>
<kwd>SDMT</kwd>
<kwd>CVLT-II</kwd>
<kwd>BVMT-R</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-1352458511431076" sec-type="intro">
<title>Introduction and rationale</title>
<p>Cognitive impairment in multiple sclerosis reduces patients’ life satisfaction and health-related quality of life. It is probably the most important determinant of employment status and associated societal costs, and also adversely affects driving safety, household task completion, social activity, physical independence, rehabilitation progress, coping, treatment adherence and mental health.<sup><xref ref-type="bibr" rid="bibr1-1352458511431076">1</xref></sup> There is a high functional impact on young adults in demanding environments. Reported cognitive impairment prevalence rates are between 43% and 70%. They occur in all disease stages, including clinically isolated syndrome (CIS) and early relapsing–remitting MS (RRMS). Cognition is only loosely related to disease duration<sup><xref ref-type="bibr" rid="bibr2-1352458511431076">2</xref></sup> and physical disability (in some instances clearly dissociated)<sup><xref ref-type="bibr" rid="bibr3-1352458511431076">3</xref></sup> and is more strongly related to brain MRI parameters, especially atrophy.<sup><xref ref-type="bibr" rid="bibr4-1352458511431076">4</xref></sup></p>
<p>Cognitive deficits typically involve a few cognitive domains, spare language and are often undetected at consultation.<sup><xref ref-type="bibr" rid="bibr5-1352458511431076">5</xref></sup> Information processing speed is the most vulnerable cognitive ability, followed by episodic memory, and executive function.<sup><xref ref-type="bibr" rid="bibr6-1352458511431076">6</xref></sup> Deficits may be mild. There is high interpatient variability, in part due to varying compensation capacities (cognitive reserve).<sup><xref ref-type="bibr" rid="bibr7-1352458511431076">7</xref></sup> Patients may not be fully aware of their deficits, or may not report them reliably: depression results in over-reporting,<sup><xref ref-type="bibr" rid="bibr8-1352458511431076">8</xref></sup> whilst metamemory impairment and insight loss lead to underestimation in up to a third.<sup><xref ref-type="bibr" rid="bibr9-1352458511431076">9</xref></sup> MS cognitive deficits occur in the context of sensory and motor impairments<sup><xref ref-type="bibr" rid="bibr10-1352458511431076">10</xref></sup> and reduced functioning and engagement is easily attributable to physical disabilities. Cognitive impairment is not always at the forefront of the neurologist’s mind, although cognitive decline could be as important to the patient as physical relapses or MRI lesions.<sup><xref ref-type="bibr" rid="bibr11-1352458511431076">11</xref></sup></p>
<p>Addressing cognitive dysfunction is recognised as a quality indicator in MS care.<sup><xref ref-type="bibr" rid="bibr12-1352458511431076">12</xref></sup> However, psychometric assessment of cognitive status requires time-consuming expert evaluation with specialist materials. The most commonly utilised batteries of neuropsychological tests validated in MS are the 45-min Brief Repeatable Battery of Neuropsychological tests (BRB-N)<sup><xref ref-type="bibr" rid="bibr13-1352458511431076">13</xref></sup> and the 90-min Minimal Assessment of Cognitive Function in MS (MACFIMS).<sup><xref ref-type="bibr" rid="bibr10-1352458511431076">10</xref></sup> Comprehensive clinical cognitive assessment requires additional expertise in test selection, administration and interpretation. This is not routinely available outside specialist centres.<sup><xref ref-type="bibr" rid="bibr10-1352458511431076">10</xref></sup> Non-specialist cognitive evaluation tools are unsatisfactory. The Expanded Disability Status Scale offers only a rudimentary estimate of cognitive function.<sup><xref ref-type="bibr" rid="bibr14-1352458511431076">14</xref></sup> Widely used screening instruments, such as the Mini Mental State Examination, are insensitive to the MS cognitive footprint.<sup><xref ref-type="bibr" rid="bibr15-1352458511431076">15</xref></sup> All of the above considerations point to a clear need for a short, well-validated and widely accepted tool, which captures the cognitive performance of MS patients, and can be used in everyday practice by clinical neurologists or administered by local healthcare workers.<sup><xref ref-type="bibr" rid="bibr16-1352458511431076">16</xref></sup></p>
</sec>
<sec id="section2-1352458511431076">
<title>Objective</title>
<p>Our objective was to recommend a clinical tool for neurologists and healthcare professionals working with people with MS, which was not designed to be either a cognitive screen or full assessment, but rather a brief monitoring instrument. It would be optimised for centres where neuropsychologists are not available. Identifying a brief measurement tool with adequate reliability, validity, sensitivity and specificity would allow for more widespread, accurate cognitive evaluations. A validated record of cognitive disability incorporated into routine clinical practise would be beneficial. Baseline ratings and regular follow-up assessments would optimise patient management. Data from this cognitive monitoring tool could assist therapeutic decision making, including determining how best to support patients’ involvement in disease management. Information and counselling could be offered, facilitating adjustment at work and home. The effect of a start or shift in Disease Modifying Drug (DMD) treatment on cognition could be monitored, and also the use of cognition enhancers (provided that sufficient evidence of efficacy is achieved).<sup><xref ref-type="bibr" rid="bibr17-1352458511431076">17</xref></sup> The brief cognitive tool could also be integrated into more detailed, specialist cognitive assessments and used to indicate which patients require expert evaluation, targeting this resource more efficiently and equitably. From a global perspective, there are currently no cognitive measures for MS that are internationally validated and standardised, which is a challenge for international study design.</p>
</sec>
<sec id="section3-1352458511431076" sec-type="methods">
<title>Methods</title>
<p>A committee of seven neurologists and five neuropsychologists was convened, selected for their expertise in research and clinical aspects of MS cognition, and to represent the language groups who had so far contributed most significantly to the MS cognition literature. There were two co-chairs (one European, one American). A list of 80 scientific articles from peer review journals (<ext-link ext-link-type="uri" xlink:href="http://msj.sagepub.com/content/early/recent" xlink:type="simple">http://msj.sagepub.com/content/early/recent</ext-link>) was assembled after a MEDLINE search in June 2010 by the co-chairs (D.L. and R.B.). These were chosen to represent a broad international spectrum of cognitive scales and their psychometric properties, including recent key review articles to allow the committee to identify any omissions. The full list was circulated to the committee and members were invited to suggest amendments and additions. Prior to the consensus meeting, a subset of articles was circulated to each committee member with standardised rating scales for completion. No member reviewed an article on which they were an author. Each article was rated independently by two committee members on three psychometric standards (reliability, validity and sensitivity) and four pragmatic standards (international applicability, ease of administration, feasibility in the specified context and acceptability to patients). All ratings were 3–1 (3 = excellent, 2 = satisfactory, 1 = unsatisfactory). The mean rating for each scale and each standard were calculated, and then the mean overall rating (MOR) for psychometric and pragmatic qualities separately. Raters were also invited to submit qualitative comments and judgements. Ratings and comments were collated for each candidate measure, and all collated ratings, from individual to mean scores, were presented to the committee and fully discussed.</p>
<sec id="section4-1352458511431076">
<title>Consensus criteria</title>
<p>To meet the specified objectives of the cognitive monitoring tool, it was decided that the recommended battery should be completed in 15 min and not require any special equipment (beyond papers, pen and stop watch) or specific assessor training. The battery should be easily performed in a clinical setting. Discussions at the consensus meeting led to agreement that the domains of information processing speed, verbal memory and visual memory could be included. Executive function scales were felt to be too long and too challenging to administer in the target context. It was acknowledged that a wide variety of cognitive presentations can be seen clinically,<sup><xref ref-type="bibr" rid="bibr18-1352458511431076">18</xref></sup> but it was felt that a battery of scales addressing the three domains identified would capture a reasonable proportion of significant cognitive impairment in large clinical samples.</p>
</sec>
<sec id="section5-1352458511431076">
<title>Recommended monitoring tests</title>
<sec id="section6-1352458511431076">
<title>Information processing speed</title>
<p>There are two widely used tests of attention and processing speed in multiple sclerosis: the Paced Auditory Serial Addition Task (PASAT)<sup><xref ref-type="bibr" rid="bibr13-1352458511431076">13</xref></sup> and the Symbol Digit Modalities Test (SDMT, oral form).<sup><xref ref-type="bibr" rid="bibr19-1352458511431076">19</xref></sup> Both are included in the BRB-N and the MACFIMS. The SDMT achieved higher ratings, with a psychometric MOR of 2.8 and a pragmatic MOR of 3.0. In comparison, the PASAT achieved a psychometric MOR of 2.6 and a pragmatic MOR of 1.9. Discussion acknowledged that the SDMT is more congenial for both patient and assessor, takes less time to complete, requires less expertise and experience of the assessor and unlike the PASAT, does not require special equipment for auditory presentation of stimuli. It has equal psychometric validity to the PASAT.<sup><xref ref-type="bibr" rid="bibr20-1352458511431076">20</xref></sup> The committee considered the evidence that the PASAT has detected therapeutic efficacy of disease modifying medication on cognition,<sup><xref ref-type="bibr" rid="bibr21-1352458511431076">21</xref>,<xref ref-type="bibr" rid="bibr22-1352458511431076">22</xref></sup> but felt that the SDMT was the better choice for the specified context on feasibility grounds.</p>
<p>The SDMT<sup><xref ref-type="bibr" rid="bibr19-1352458511431076">19</xref></sup> was recommended as the test of information processing speed. The test consists of single digits paired with abstract symbols (<xref ref-type="fig" rid="fig1-1352458511431076">Figure 1</xref>). Rows of the nine symbols are arranged pseudo-randomly. The patient must say the number that corresponds with each symbol. The SDMT can be completed within 5 min, including instructions, practice and testing. The good psychometric properties of the SDMT are well described.<sup><xref ref-type="bibr" rid="bibr23-1352458511431076">23</xref></sup> The SDMT has a reported sensitivity of 82% and a specificity of 60%.<sup><xref ref-type="bibr" rid="bibr24-1352458511431076">24</xref></sup> It has validations in several countries.<sup><xref ref-type="bibr" rid="bibr2-1352458511431076">2</xref>,<xref ref-type="bibr" rid="bibr24-1352458511431076">24</xref><xref ref-type="bibr" rid="bibr25-1352458511431076"/>–<xref ref-type="bibr" rid="bibr26-1352458511431076">26</xref></sup> Estimates of practice effects and change indices are available.<sup><xref ref-type="bibr" rid="bibr27-1352458511431076">27</xref></sup> The SDMT has a high sensitivity to cognitive impairment in MS.<sup><xref ref-type="bibr" rid="bibr6-1352458511431076">6</xref>,<xref ref-type="bibr" rid="bibr26-1352458511431076">26</xref>,<xref ref-type="bibr" rid="bibr28-1352458511431076">28</xref></sup> It has been shown to be the best predictor of MS cognitive impairment in both the BRB-N and MACFIMS.<sup><xref ref-type="bibr" rid="bibr6-1352458511431076">6</xref></sup> The SDMT is reliable when administered by nursing staff over several months, with minimal practice effects (0.2).<sup><xref ref-type="bibr" rid="bibr29-1352458511431076">29</xref></sup> There is also evidence for the sensitivity of the SDMT to cognitive change in MS.<sup><xref ref-type="bibr" rid="bibr2-1352458511431076">2</xref>,<xref ref-type="bibr" rid="bibr25-1352458511431076">25</xref>,<xref ref-type="bibr" rid="bibr30-1352458511431076">30</xref></sup> The SDMT is well validated against both conventional brain MRI parameters (including atrophy,<sup><xref ref-type="bibr" rid="bibr31-1352458511431076">31</xref></sup> brain parenchymal fraction (BPF) and third ventricular width,<sup><xref ref-type="bibr" rid="bibr32-1352458511431076">32</xref></sup> atrophy at baseline predicting SDMT change;<sup><xref ref-type="bibr" rid="bibr33-1352458511431076">33</xref></sup> cortical lesion number and white matter lesion volume,<sup><xref ref-type="bibr" rid="bibr34-1352458511431076">34</xref></sup> cortical lesion volume,<sup><xref ref-type="bibr" rid="bibr32-1352458511431076">32</xref>,<xref ref-type="bibr" rid="bibr34-1352458511431076">34</xref>.<xref ref-type="bibr" rid="bibr35-1352458511431076">35</xref></sup> cortical lesion volume change correlating with SDMT change,<sup><xref ref-type="bibr" rid="bibr36-1352458511431076">36</xref></sup> correlation with some deep grey matter (DGM) nuclei,<sup><xref ref-type="bibr" rid="bibr37-1352458511431076">37</xref></sup> including thalamic fraction;<sup><xref ref-type="bibr" rid="bibr32-1352458511431076">32</xref></sup> and fMRI (fractional anisotropy).<sup><xref ref-type="bibr" rid="bibr38-1352458511431076">38</xref></sup> The SDMT has also been shown to have external clinical validity, being significantly linked to both current<sup><xref ref-type="bibr" rid="bibr39-1352458511431076">39</xref></sup> and future<sup><xref ref-type="bibr" rid="bibr30-1352458511431076">30</xref></sup> employment status.</p>
<fig id="fig1-1352458511431076" position="float">
<label>Figure 1.</label>
<caption><p>Example of stimuli of the SDMT type.</p></caption>
<graphic alt-version="no" position="float" xlink:href="10.1177_1352458511431076-fig1.tif" xlink:type="simple"/>
</fig>
</sec>
<sec id="section7-1352458511431076">
<title>Verbal memory (immediate recall)</title>
<p>Again two candidate scales emerged: The California Verbal Learning Test-II (CVLT-II)<sup><xref ref-type="bibr" rid="bibr40-1352458511431076">40</xref></sup> and the Selective Reminding Test (SRT).<sup><xref ref-type="bibr" rid="bibr13-1352458511431076">13</xref></sup> The CVLT-II is in the MACFIMS and the SRT is in the BRB-N. The CVLT-II achieved a psychometric MOR of 2.9 and a pragmatic MOR of 2.6. In contrast, the SRT achieved a psychometric MOR of 2.5 and a pragmatic MOR of 2.2. It was noted that the SRT format required more expertise in administration and scoring, compared to the simple list recall format of the CVLT-II. The committee decided that the first five recall trials of the CVLT-II (CVLT-II T1-5) had sufficient psychometric rigour, in particular sensitivity to MS impairment,<sup><xref ref-type="bibr" rid="bibr41-1352458511431076">41</xref>,<xref ref-type="bibr" rid="bibr42-1352458511431076">42</xref></sup> to be suitable for inclusion in BICAMS. CVLT-II T1-5 has been previously recommended as part of a brief MS cognitive assessment.<sup><xref ref-type="bibr" rid="bibr43-1352458511431076">43</xref></sup> The first five recall trials have a high degree of interdependence to other sections of the CVLT-II.<sup><xref ref-type="bibr" rid="bibr42-1352458511431076">42</xref></sup> Although this renders conclusions from the validity data based on the full CVLT-II inferential, it also reduces the range of cognitive processes involved.<sup><xref ref-type="bibr" rid="bibr41-1352458511431076">41</xref></sup> The recommendation carries the pragmatic advantage of reduced administration time (and possible patient fatigue effects), and a lesser requirement for assessor expertise and experience compared to the full CVLT-II, which suit our target context.</p>
<p>The recommended verbal memory scale is the CVLT-II T1-5.<sup><xref ref-type="bibr" rid="bibr40-1352458511431076">40</xref></sup> This comprises a 16-item word list, with four items belonging to each of four categories, arranged randomly (<xref ref-type="fig" rid="fig2-1352458511431076">Figure 2</xref>). The list is read aloud five times in the same order to the patient, at a slightly slower rate than one item per second. Patients are required to recall as many items as possible, in any order, after each reading of the list. The CVLT-II T1-5 can be completed in 5–10 min, including instructions, testing and responses. The CVLT-II T1-5 has been validated with brain MR total lesion area and right superior frontal atrophy,<sup><xref ref-type="bibr" rid="bibr44-1352458511431076">44</xref></sup> MR T1 and FLAIR lesion volume, BPF and third ventricular width<sup><xref ref-type="bibr" rid="bibr32-1352458511431076">32</xref></sup> and MR diffusion measures.<sup><xref ref-type="bibr" rid="bibr42-1352458511431076">42</xref></sup> The full CVLT-II has been validated against brain MRI parameters (cortical lesion number;<sup><xref ref-type="bibr" rid="bibr34-1352458511431076">34</xref></sup> correlation with some DGM nuclei volume,<sup><xref ref-type="bibr" rid="bibr37-1352458511431076">37</xref></sup> including thalamic fraction).<sup><xref ref-type="bibr" rid="bibr32-1352458511431076">32</xref></sup> The full CVLT-II also has external clinical validity, in differentiating employed MS patients from patients not employed due to MS.<sup><xref ref-type="bibr" rid="bibr41-1352458511431076">41</xref></sup></p>
<fig id="fig2-1352458511431076" position="float">
<label>Figure 2.</label>
<caption><p>Example stimuli of the CVLT-II type.</p></caption>
<graphic alt-version="no" position="float" xlink:href="10.1177_1352458511431076-fig2.tif" xlink:type="simple"/>
</fig>
</sec>
<sec id="section8-1352458511431076">
<title>Visual Memory (immediate recall)</title>
<p>Once again, two major candidate scales emerged: the Brief Visuospatial Memory Test Revised (BVMT-R)<sup><xref ref-type="bibr" rid="bibr45-1352458511431076">45</xref></sup> and the 10/36 Spatial Recall Test.<sup><xref ref-type="bibr" rid="bibr13-1352458511431076">13</xref></sup> The BVMT-R is in the MACFIMS and the 10/36 is in the BRB-N. The BVMT-R achieved a psychometric MOR of 3.0 and a pragmatic MOR of 2.2. In comparison, the 10/36 achieved a psychometric MOR of 2.3 and a pragmatic MOR of 2.6. The committee’s discussion highlighted the reliability of the BVMT-R, the special equipment needed for the 10/36 and the possible ceiling effect on the 10/36.<sup><xref ref-type="bibr" rid="bibr7-1352458511431076">7</xref>,<xref ref-type="bibr" rid="bibr28-1352458511431076">28</xref></sup> As in the deliberations about the verbal memory scale, the conclusion was reached that the first three recall trials of the BVMT-R (BVMTR T1-3) would be the scale recommended for BICAMS, with similar advantages and caveats to those stated above in connection with the CVLT-II T1-5.</p>
<p>The BVMT-R T1-3<sup><xref ref-type="bibr" rid="bibr45-1352458511431076">45</xref></sup> is recommended. The BVMT-R T1-3 requires the patient to inspect a 2 × 3 stimulus array of abstract geometric figures (<xref ref-type="fig" rid="fig3-1352458511431076">Figure 3</xref>). There are three learning trials of 10 s. The array is removed and the patient is required to draw the array from memory, with the correct shapes in the correct position. The psychometric properties of the BVMT-R T1-3 are good.<sup><xref ref-type="bibr" rid="bibr45-1352458511431076">45</xref></sup> Validity of the BVMT-R T1-3 has been indicated by significant association with brain MR total lesion area,<sup><xref ref-type="bibr" rid="bibr44-1352458511431076">44</xref></sup> T1 lesion and FLAIR lesion volume, BPF and third ventricular width<sup><xref ref-type="bibr" rid="bibr32-1352458511431076">32</xref></sup> and right superior frontal atrophy<sup><xref ref-type="bibr" rid="bibr44-1352458511431076">44</xref></sup> and correlation with some DGM nuclei,<sup><xref ref-type="bibr" rid="bibr37-1352458511431076">37</xref></sup> including thalamic fraction.<sup><xref ref-type="bibr" rid="bibr32-1352458511431076">32</xref></sup></p>
<fig id="fig3-1352458511431076" position="float">
<label>Figure 3.</label>
<caption><p>Example test stimuli of the BVMT-R type.</p></caption>
<graphic alt-version="no" position="float" xlink:href="10.1177_1352458511431076-fig3.tif" xlink:type="simple"/>
</fig>
</sec>
</sec>
</sec>
<sec id="section9-1352458511431076">
<title>Implementation</title>
<p>For those health professionals with little experience of cognitive assessment, prior review of instructions and practice is recommended. Testing should take place in a quiet room, with just the patient and the assessor present. The purpose of BICAMS should be explained to the patient and if appropriate, some background information explaining cognitive difficulties in MS should have been made available to the patient in advance (e.g. <ext-link ext-link-type="uri" xlink:href="http://www.stayingsmart.org.uk" xlink:type="simple">www.stayingsmart.org.uk</ext-link>). It is recommended that BICAMS should not be used within 1 month of recovery from relapse (or if used, the data should not be interpreted as indicating long-term decline),<sup><xref ref-type="bibr" rid="bibr46-1352458511431076">46</xref></sup> or within 1 month of steroid therapy, which has a proven reversible detrimental effect on memory function.<sup><xref ref-type="bibr" rid="bibr47-1352458511431076">47</xref></sup> The recommended order of administration is first the SDMT, then if time allows the CVLT-II T1-5 and BVMT-R T1-3. In most clinical situations, yearly or bi-annual BICAMS evaluations will be appropriate.</p>
<sec id="section10-1352458511431076">
<title>Confounds and limitations</title>
<p>BICAMS is not intended to replace a full neuropsychological assessment, which provides important additional insights to the patient, family, and clinician. These more detailed evaluations are necessary for in depth rehabilitation and vocational counselling and disability determination.</p>
<p>Neuropsychological test performance, including measures such as the SDMT, CVLT-II, and BVMT-R, is influenced by MS physical symptoms, demographic factors, the presence of concurrent neurological disorders other than MS, some concurrent medications, and to a modest degree depression.</p>
<sec id="section11-1352458511431076">
<title>Physical symptoms of MS</title>
<p>Whilst the BICAMS component scales have been selected to minimise the impact of physical impairments on cognitive test performance,<sup><xref ref-type="bibr" rid="bibr10-1352458511431076">10</xref>,<xref ref-type="bibr" rid="bibr13-1352458511431076">13</xref></sup> the assessor should remain aware of confounds from MS symptoms. For example, dysarthria reduces performance on tests requiring a spoken response, especially if timed.<sup><xref ref-type="bibr" rid="bibr48-1352458511431076">48</xref></sup> Even mild MS visual impairments can also affect cognitive tests with visual stimuli.<sup><xref ref-type="bibr" rid="bibr49-1352458511431076">49</xref></sup> The experienced clinician can infer how a patient’s physical difficulties prejudice their test scores. Aside from the sensory and motor interface with the test situation, there are a number of physical symptoms of MS that can interfere with cognitive test performance, notably pain.<sup><xref ref-type="bibr" rid="bibr10-1352458511431076">10</xref></sup></p>
</sec>
<sec id="section12-1352458511431076">
<title>Demographic factors</title>
<p>Demographic factors (age, education, and gender) affect cognitive performance. Many tests have normative data taking account of these variables.<sup><xref ref-type="bibr" rid="bibr50-1352458511431076">50</xref>,<xref ref-type="bibr" rid="bibr51-1352458511431076">51</xref></sup> It is also well established that pre-morbid optimal level will affect how far current deterioration is detectable (cognitive reserve).<sup><xref ref-type="bibr" rid="bibr7-1352458511431076">7</xref></sup> Some countries have reading scales that estimate pre-morbid level.<sup><xref ref-type="bibr" rid="bibr10-1352458511431076">10</xref></sup> If testing materials are not available in the patient’s native language, particularly with respect to verbal learning and memory, published normative data cannot be used with any precision to evaluate the patient’s performance. The limited value of BICAMS for patients who are not native speakers is as a baseline against which to measure future change.</p>
</sec>
<sec id="section13-1352458511431076">
<title>Concurrent neurological/medical disorders</title>
<p>If an MS patient has cognitive dysfunction, consideration must be give to whether other co-morbid neurological or medical conditions exist. In the context of learning disability, most mainstream intellectual assessments are inappropriate. It is helpful to ask whether or not a diagnosis of learning difficulty or attention deficit disorder was present prior to the MS diagnosis, or their characteristic features, since these conditions may have been present without formally diagnosis. Questions regarding difficulties in school performance or with reading can yield helpful information. The medical history should include questions regarding past head trauma, cerebrovascular disease, and other medical conditions such as sleep apnoea.</p>
</sec>
<sec id="section14-1352458511431076">
<title>Concurrent medications</title>
<p>Certain medications commonly used in MS can adversely affect cognitive functioning.<sup><xref ref-type="bibr" rid="bibr52-1352458511431076">52</xref></sup> Benzodiazepines can interfere with vigilance and memory.<sup><xref ref-type="bibr" rid="bibr53-1352458511431076">53</xref></sup> For many patients high doses of anti-spasticity agents such as baclofen are associated with cognitive impairments.<sup><xref ref-type="bibr" rid="bibr54-1352458511431076">54</xref></sup> Anticonvulsants are also known to reduce cognitive function.<sup><xref ref-type="bibr" rid="bibr55-1352458511431076">55</xref></sup> Antidepressant medication can cause cognitive inefficiency to varying degrees.<sup><xref ref-type="bibr" rid="bibr52-1352458511431076">52</xref></sup> Cannabis, whether prescribed or self-medicated, can influence cognition.<sup><xref ref-type="bibr" rid="bibr56-1352458511431076">56</xref></sup> It is also important to be alert to other non-prescribed medication. Recent changes in cognition should be considered in the context of any concurrent medication changes.</p>
</sec>
<sec id="section15-1352458511431076">
<title>Depression</title>
<p>Depression is highly prevalent in MS and may have mild effects on cognitive functioning, possibly mediated by coping styles.<sup><xref ref-type="bibr" rid="bibr57-1352458511431076">57</xref></sup> It is likely that severe depression could interfere with either willingness to undergo testing or ability to concentrate. An important aspect of depression’s influence on the clinical management of cognition, is that depression affects self-report of cognitive problems. Patients’ self-report of cognitive impairment does not reliably correlate with their performance at objective cognitive testing; in contrast, the relative’s report of the patient’s cognitive status does correlate with the patient’s performance at objective cognitive testing.<sup><xref ref-type="bibr" rid="bibr58-1352458511431076">58</xref></sup> Treatment of depression (and fatigue) improves patients’ self report of cognitive function, but not their objective cognitive test performance.<sup><xref ref-type="bibr" rid="bibr8-1352458511431076">8</xref></sup></p>
</sec>
<sec id="section16-1352458511431076">
<title>Fatigue</title>
<p>Over 80% of MS patients experience fatigue and also have the impression that this symptom interferes with their cognitive functions.<sup><xref ref-type="bibr" rid="bibr59-1352458511431076">59</xref></sup> This association has not been consistently confirmed in studies of objective cognitive test performance. However, it is known that heat, infections, pain and depression can increase fatigue and these contributory factors should be managed to ensure optimum cognitive performance. When feasible, patients should be allowed to rest after arriving, before their cognitive assessment, to minimise the effects of fatigue.<sup><xref ref-type="bibr" rid="bibr60-1352458511431076">60</xref></sup> Those undergoing repeated testing should if possible be evaluated at the same time of day as the original assessment, to avoid variance from time of day fatigue effects.</p>
</sec>
</sec>
</sec>
<sec id="section17-1352458511431076">
<title>Future work and development of BICAMS</title>
<p>An international validation protocol for BICAMS is under development. Several national validation and standardisation projects are under way. It is envisaged that over time, many nations will be able to utilise BICAMS as part of routine clinical MS practice, referring to appropriate national norms. International MS natural history studies and treatment trials with cognition outcomes will be assisted by an internationally standardised battery. In order to support this process and facilitate access to materials and norms, the BICAMS committee is working to publish BICAMS updates in scientific and professional journals and meetings. The BICAMS website (<ext-link ext-link-type="uri" xlink:href="http://www.BICAMS.net" xlink:type="simple">www.BICAMS.net</ext-link>) will be a focus for this process, with a commitment to open access whenever possible.</p>
</sec>
<sec id="section18-1352458511431076">
<title>Summary</title>
<p>An expert consensus committee of neurologists and neuropsychologists, with extensive research and clinical experience of MS cognition, have recommended a Brief International Assessment of Cognition for MS (BICAMS).<sup><xref ref-type="bibr" rid="bibr16-1352458511431076">16</xref></sup> The battery takes 15 min to complete, requires no specialist equipment and no specialist expertise in cognitive assessment. BICAMS comprises:</p>
<list id="list1-1352458511431076" list-type="bullet">
<list-item><p>The Symbol Digit Modalities Test</p></list-item>
<list-item><p>The California Verbal Learning Test –II, first five recall trials</p></list-item>
<list-item><p>The Brief Visuospatial Memory Test –Revised, first three recall trials.</p></list-item>
</list>
</sec>
</body>
<back>
<ack>
<p>This group of authors first came together in a Bayer sponsored meeting, which inspired the foundation of the (independent) BICAMS committee. We acknowledge Bayer’s scientific contribution in the area of cognition.</p>
</ack>
<fn-group>
<fn fn-type="financial-disclosure">
<p>The BICAMS committee meetings are sponsored by Bayer.</p></fn>
<fn fn-type="conflict">
<p>Professor Langdon has received funding for travel to scientific meetings from Bayer Healthcare; serves on a Steering Committee for Bayer Healthcare; has served/serves as a consultant to Merck-Serono, Bayer Healthcare; served on speaker bureau for Bayer Healthcare, Roche, Serono Symposia, TEVA Germany; receives research contract funding from Bayer Healthcare; receives educational grants from Bayer Healthcare.</p>
<p>Professor Amato received personal compensation from Merck Serono, Biogen Dompè, Sanofi Aventis, Bayer Schering for serving on scientific advisory board and for speaking. Professor Amato received financial support for research activities from Merck Serono, Sanofi Aventis, Biogen Dompè, Bayer Schering.</p>
<p>Dr Boringa has consulted for Bayer Healthcare served on speaker bureau for Exencia Pharma Academy.</p>
<p>Dr Brochet serves on scientific advisory boards for Bayer Schering Pharma, Novartis, and Merck Serono; has received funding for travel and speaker honoraria from Bayer Schering Pharma, Merck Serono, Biogen Idec, AB Sciences, and Teva Pharmaceutical Industries Ltd./Sanofi-Aventis; and serves as LEN editor for SEP et Neurosciences.</p>
<p>Dr Foley has received honoraria for speaking at scientific and patient-education meetings, serving on scientific advisory boards and consulting activities from Bayer–Schering, Biogen, and Teva Neuroscience.</p>
<p>Dr Fredrikson has received honoraria for lectures, educational activities and consultancy from Bayer, Biogen Idec and Sanofi–Aventis during the past year.</p>
<p>Dr Hämäläinen received personal compensation from Bayer Healthcare and Novartis for serving on scientific advisory boards; consulting for Sanofi–Aventis; served on speaker bureau for Bayer Healthcare and Sanofi–Aventis.</p>
<p>Professor Hartung received honoraria with approval by the Rector of Heinrich-Heine-University from Bayer Healthcare GmbH, Octapharma GmbH, Novartis, Teva Sanofi Aventis, Biogen Idec GmbH and Merck Serono GmBH for consulting and speaking at scientific symposia.</p>
<p>Dr Krupp has served on speaker bureaux, scientific advisory boards and/or been a consultant for Teva Neurosciences, BiogenIdec, EMD Serono, Multiple Sclerosis Association of America, Betaseron/Bayer Healthcare Pharmaceuticals, Pfizer, Sanofi–Aventis, Axon Advisors; she has received royalties from Genzyme, ER Squibb &amp; Sons, NMSS, Novartis, MedImmune, Abbott Laboratories, Johnson&amp;Johnson, Roche, Health Professions Conferencing Corp.</p>
<p>Dr Penner has received honoraria for speaking at scientific meetings, serving at scientific advisory boards and consulting activities from Bayer–Schering, Biogen, Merck Serono, Roche, Novartis.</p>
<p>Dr Reder has recently submitted two articles to <italic>Neurology</italic> and his disclosures remain the same.</p>
<p>Professor Benedict has acted as a consultant or scientific advisory board member for Bayer, Biogen Idec, Merk Serono, EMD Serono, Pfizer, Novartis; royalties from Psychological Assessment Resources, Inc; financial support for research activities from Shire Pharmaceuticals, Biogen Idec.</p></fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-1352458511431076">
<label>1.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Langdon</surname><given-names>DW</given-names></name>
</person-group>. <article-title>Cognition in multiple sclerosis</article-title>. <source>Curr Opin Neurol</source> <year>2011</year>; <volume>24</volume>: <fpage>244</fpage>–<lpage>249</lpage>.</citation>
</ref>
<ref id="bibr2-1352458511431076">
<label>2.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Amato</surname><given-names>MP</given-names></name>
<name name-style="western"><surname>Portaccio</surname><given-names>E</given-names></name>
<name name-style="western"><surname>Goretti</surname><given-names>B</given-names></name><etal/>
</person-group>. <article-title>Relevance of cognitive deterioration in early relapsing–remitting MS: a 3-year follow-up study</article-title>. <source>Mult Scler</source> <year>2010</year>; <volume>16</volume>: <fpage>1474</fpage>–<lpage>1482</lpage>.</citation>
</ref>
<ref id="bibr3-1352458511431076">
<label>3.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Amato</surname><given-names>MP</given-names></name>
<name name-style="western"><surname>Portaccio</surname><given-names>E</given-names></name>
<name name-style="western"><surname>Stromillo</surname><given-names>ML</given-names></name><etal/>
</person-group>. <article-title>Cognitive assessment and quantitative magnetic resonance metrics can help to identify benign multiple sclerosis</article-title>. <source>Neurology</source> <year>2008</year>; <volume>71</volume>: <fpage>632</fpage>–<lpage>638</lpage>.</citation>
</ref>
<ref id="bibr4-1352458511431076">
<label>4.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Filippi</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Rocca</surname><given-names>MA</given-names></name>
<name name-style="western"><surname>Benedict</surname><given-names>RH</given-names></name>
<etal/>
</person-group>. <article-title>The contribution of MRI in assessing cognitive impairment in multiple sclerosis</article-title>. <source>Neurology</source> <year>2010</year>; <volume>75</volume>: <fpage>2121</fpage>–<lpage>2128</lpage>.</citation>
</ref>
<ref id="bibr5-1352458511431076">
<label>5.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Langdon</surname><given-names>D</given-names></name>
</person-group>. <article-title>Cognitive impairment in multiple sclerosis – recent advances and future prospects</article-title>. <source>Eur Neurol Rev</source> <year>2010</year>; <volume>5</volume>: <fpage>69</fpage>–<lpage>72</lpage>.</citation>
</ref>
<ref id="bibr6-1352458511431076">
<label>6.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Strober</surname><given-names>L</given-names></name>
<name name-style="western"><surname>Englert</surname><given-names>J</given-names></name>
<name name-style="western"><surname>Munschauer</surname><given-names>F</given-names></name>
<etal/>
</person-group>. <article-title>Sensitivity of conventional memory tests in multiple sclerosis: comparing the Rao Brief Repeatable Neuropsychological Battery and the Minimal Assessment of Cognitive Function in MS</article-title>. <source>Mult Scler</source> <year>2009</year>; <volume>15</volume>: <fpage>1077</fpage>–<lpage>1084</lpage>.</citation>
</ref>
<ref id="bibr7-1352458511431076">
<label>7.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Sumowski</surname><given-names>JF</given-names></name>
<name name-style="western"><surname>Wylie</surname><given-names>GR</given-names></name>
<name name-style="western"><surname>Chiaravalloti</surname><given-names>N</given-names></name>
<name name-style="western"><surname>DeLuca</surname><given-names>J</given-names></name>
</person-group>. <article-title>Intellectual enrichment lessens the effect of brain atrophy on learning and memory in multiple sclerosis</article-title>. <source>Neurology</source> <year>2010</year>; <volume>74</volume>: <fpage>1942</fpage>–<lpage>1945</lpage>.</citation>
</ref>
<ref id="bibr8-1352458511431076">
<label>8.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Kinsinger</surname><given-names>SW</given-names></name>
<name name-style="western"><surname>Lattie</surname><given-names>E</given-names></name>
<name name-style="western"><surname>Mohr</surname><given-names>DC</given-names></name>
</person-group>. <article-title>Relationship between depression, fatigue, subjective cognitive impairment, and objective neuropsychological functioning in patients with multiple sclerosis</article-title>. <source>Neuropsychology</source> <year>2010</year>; <volume>24</volume>: <fpage>573</fpage>–<lpage>580</lpage>.</citation>
</ref>
<ref id="bibr9-1352458511431076">
<label>9.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Sherman</surname><given-names>TE</given-names></name>
<name name-style="western"><surname>Rapport</surname><given-names>LJ</given-names></name>
<name name-style="western"><surname>Ryan</surname><given-names>KA</given-names></name>
</person-group>. <article-title>Awareness of deficit in multiple sclerosis</article-title>. <source>J Clin Exp Neuropsychol</source> <year>2008</year>; <volume>30</volume>: <fpage>301</fpage>–<lpage>311</lpage>.</citation>
</ref>
<ref id="bibr10-1352458511431076">
<label>10.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Benedict</surname><given-names>RH</given-names></name>
<name name-style="western"><surname>Fischer</surname><given-names>JS</given-names></name>
<name name-style="western"><surname>Archibald</surname><given-names>CJ</given-names></name>
<etal/>
</person-group>. <article-title>Minimal neuropsychological assessment of MS patients: a consensus approach</article-title>. <source>The Clinical Neuropsychologist</source> <year>2002</year>; <volume>16</volume>: <fpage>381</fpage>–<lpage>397</lpage>.</citation>
</ref>
<ref id="bibr11-1352458511431076">
<label>11.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Sicotte</surname><given-names>NL</given-names></name>
</person-group>. <article-title>Neuroimaging in multiple sclerosis: neurotherapeutic implications</article-title>. <source>Neurotherapeutics</source> <year>2011</year>; <volume>8</volume>: <fpage>54</fpage>–<lpage>62</lpage>.</citation>
</ref>
<ref id="bibr12-1352458511431076">
<label>12.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Cheng</surname><given-names>EM</given-names></name>
<name name-style="western"><surname>Crandall</surname><given-names>CJ</given-names></name>
<name name-style="western"><surname>Bever</surname><given-names>CT</given-names></name>
<etal/>
</person-group>. <article-title>Quality indicators for multiple sclerosis</article-title>. <source>Mult Scler</source> <year>2010</year>; <volume>16</volume>: <fpage>970</fpage>–<lpage>980</lpage>.</citation>
</ref>
<ref id="bibr13-1352458511431076">
<label>13.</label>
<citation citation-type="book" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Rao</surname><given-names>SM</given-names></name>
</person-group>, <collab xlink:type="simple">the Cognitive Function Study Group of the National Multiple Sclerosis Society</collab>. <source>A Manual for the Brief Repeatable Battery of Neuropsychological Tests in Multiple Sclerosis</source>. <publisher-loc>Milwaukee, WI</publisher-loc>: <publisher-name>Medical College of Wisconsin</publisher-name>; <year>1990</year>.</citation>
</ref>
<ref id="bibr14-1352458511431076">
<label>14.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Marrie</surname><given-names>RA</given-names></name>
<name name-style="western"><surname>Goldman</surname><given-names>M</given-names></name>
</person-group>. <article-title>Validity of performance scales for disability assessment in multiple sclerosis</article-title>. <source>Mult Scler</source> <year>2007</year>; <volume>13</volume>: <fpage>1176</fpage>–<lpage>1182</lpage>.</citation>
</ref>
<ref id="bibr15-1352458511431076">
<label>15.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Aupperle</surname><given-names>RL</given-names></name>
<name name-style="western"><surname>Beatty</surname><given-names>WW</given-names></name>
<name name-style="western"><surname>Shelton Fde</surname><given-names>N</given-names></name>
<name name-style="western"><surname>Gontkovsky</surname><given-names>ST</given-names></name>
</person-group>. <article-title>Three screening batteries to detect cognitive impairment in multiple sclerosis</article-title>. <source>Mult Scler</source> <year>2002</year>; <volume>8</volume>: <fpage>382</fpage>–<lpage>389</lpage>.</citation>
</ref>
<ref id="bibr16-1352458511431076">
<label>16.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Langdon</surname><given-names>D</given-names></name>
<name name-style="western"><surname>Amato</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Boringa</surname><given-names>J</given-names></name>
<etal/>
</person-group>. <article-title>The Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS): first consensus steps towards a brief universal cognitive assessment for MS</article-title>. <source>Neurology</source> <year>2011</year>; <volume>76</volume>: <fpage>A479</fpage>.</citation>
</ref>
<ref id="bibr17-1352458511431076">
<label>17.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Christodoulou</surname><given-names>C</given-names></name>
<name name-style="western"><surname>MacAllister</surname><given-names>WS</given-names></name>
<name name-style="western"><surname>McLinskey</surname><given-names>NA</given-names></name>
<name name-style="western"><surname>Krupp</surname><given-names>LB</given-names></name>
</person-group>. <article-title>Treatment of cognitive impairment in multiple sclerosis: is the use of acetylcholinesterase inhibitors a viable option?</article-title> <source>CNS Drugs</source> <year>2008</year>; <volume>22</volume>: <fpage>87</fpage>–<lpage>97</lpage>.</citation>
</ref>
<ref id="bibr18-1352458511431076">
<label>18.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Prakash</surname><given-names>RS</given-names></name>
<name name-style="western"><surname>Snook</surname><given-names>EM</given-names></name>
<name name-style="western"><surname>Lewis</surname><given-names>JM</given-names></name>
<name name-style="western"><surname>Motl</surname><given-names>RW</given-names></name>
<name name-style="western"><surname>Kramer</surname><given-names>AF</given-names></name>
</person-group>. <article-title>Cognitive impairments in relapsing–remitting multiple sclerosis: a meta-analysis</article-title>. <source>Mult Scler</source> <year>2008</year>; <volume>14</volume>: <fpage>1250</fpage>–<lpage>1261</lpage>.</citation>
</ref>
<ref id="bibr19-1352458511431076">
<label>19.</label>
<citation citation-type="book" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Smith</surname><given-names>A</given-names></name>
</person-group>. <source>Symbol Digit Modalities Test (SDMT) Manual</source> (<comment>revised</comment>). <publisher-loc>Los Angeles</publisher-loc>: <publisher-name>Western Psychological Services</publisher-name>; <year>1982</year>.</citation>
</ref>
<ref id="bibr20-1352458511431076">
<label>20.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Drake</surname><given-names>AS</given-names></name>
<name name-style="western"><surname>Weinstock-Guttman</surname><given-names>B</given-names></name>
<name name-style="western"><surname>Morrow</surname><given-names>SA</given-names></name>
<name name-style="western"><surname>Hojnacki</surname><given-names>D</given-names></name>
<name name-style="western"><surname>Munschauer</surname><given-names>FE</given-names></name>
<name name-style="western"><surname>Benedict</surname><given-names>RH</given-names></name>
</person-group>. <article-title>Psychometrics and normative data for the Multiple Sclerosis Functional Composite: replacing the PASAT with the Symbol Digit Modalities Test</article-title>. <source>Mult Scler</source> <year>2010</year>; <volume>16</volume>: <fpage>228</fpage>–<lpage>237</lpage>.</citation>
</ref>
<ref id="bibr21-1352458511431076">
<label>21.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Fischer</surname><given-names>JS</given-names></name>
<name name-style="western"><surname>Priore</surname><given-names>RL</given-names></name>
<name name-style="western"><surname>Jacobs</surname><given-names>LD</given-names></name>
<etal/>
</person-group>. <article-title>Neuropsychological effects of interferon beta-1a in relapsing multiple sclerosis</article-title>. <source>Ann Neurol</source> <year>2000</year>; <volume>48</volume>: <fpage>885</fpage>–<lpage>92</lpage>.</citation>
</ref>
<ref id="bibr22-1352458511431076">
<label>22.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Kappos</surname><given-names>L</given-names></name>
<name name-style="western"><surname>Freedman</surname><given-names>MS</given-names></name>
<name name-style="western"><surname>Polman</surname><given-names>CH</given-names></name>
<etal/>
</person-group>. <article-title>Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial</article-title>. <source>Lancet Neurol</source> <year>2009</year>; <volume>8</volume>: <fpage>987</fpage>–<lpage>997</lpage>.</citation>
</ref>
<ref id="bibr23-1352458511431076">
<label>23.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Benedict</surname><given-names>RH</given-names></name>
<name name-style="western"><surname>Cookfair</surname><given-names>D</given-names></name>
<name name-style="western"><surname>Gavett</surname><given-names>R</given-names></name>
<etal/>
</person-group>. <article-title>Validity of the minimal assessment of cognitive function in multiple sclerosis (MACFIMS)</article-title>. <source>J Int Neuropsychol Soc</source> <year>2006</year>; <volume>12</volume>: <fpage>549</fpage>–<lpage>558</lpage>.</citation>
</ref>
<ref id="bibr24-1352458511431076">
<label>24.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Parmenter</surname><given-names>BA</given-names></name>
<name name-style="western"><surname>Weinstock-Guttman</surname><given-names>B</given-names></name>
<name name-style="western"><surname>Garg</surname><given-names>N</given-names></name>
<name name-style="western"><surname>Munschauer</surname><given-names>F</given-names></name>
<name name-style="western"><surname>Benedict</surname><given-names>RH</given-names></name>
</person-group>. <article-title>Screening for cognitive impairment in multiple sclerosis using the Symbol Digit Modalities Test</article-title>. <source>Mult Scler</source> <year>2007</year>; <volume>13</volume>: <fpage>52</fpage>–<lpage>57</lpage>.</citation>
</ref>
<ref id="bibr25-1352458511431076">
<label>25.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Holmén</surname><given-names>C</given-names></name>
<name name-style="western"><surname>Piehl</surname><given-names>F</given-names></name>
<name name-style="western"><surname>Hillert</surname><given-names>J</given-names></name>
<etal/>
</person-group>. <article-title>A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis</article-title>. <source>Mult Scler</source> <year>2011</year>; <volume>17</volume>: <fpage>708</fpage>–<lpage>719</lpage>.</citation>
</ref>
<ref id="bibr26-1352458511431076">
<label>26.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Deloire</surname><given-names>MS</given-names></name>
<name name-style="western"><surname>Bonnet</surname><given-names>MC</given-names></name>
<name name-style="western"><surname>Salort</surname><given-names>E</given-names></name>
<etal/>
</person-group>. <article-title>How to detect cognitive dysfunction at early stages of multiple sclerosis?</article-title> <source>Mult Scler</source> <year>2006</year>; <volume>12</volume>: <fpage>445</fpage>–<lpage>452</lpage>.</citation>
</ref>
<ref id="bibr27-1352458511431076">
<label>27.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Portaccio</surname><given-names>E</given-names></name>
<name name-style="western"><surname>Goretti</surname><given-names>B</given-names></name>
<name name-style="western"><surname>Zipoli</surname><given-names>V</given-names></name>
<etal/>
</person-group>. <article-title>Reliability, practice effects, and change indices for Rao’s Brief Repeatable Battery</article-title>. <source>Mult Scler</source> <year>2010</year>; <volume>16</volume>: <fpage>611</fpage>–<lpage>617</lpage>.</citation>
</ref>
<ref id="bibr28-1352458511431076">
<label>28.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Camp</surname><given-names>SJ</given-names></name>
<name name-style="western"><surname>Stevenson</surname><given-names>VL</given-names></name>
<name name-style="western"><surname>Thompson</surname><given-names>AJ</given-names></name>
<etal/>
</person-group>. <article-title>Cognitive function in primary progressive and transitional progressive multiple sclerosis: a controlled study with MRI correlates</article-title>. <source>Brain</source> <year>1999</year>; <volume>122</volume>: <fpage>1341</fpage>–<lpage>1348</lpage>.</citation>
</ref>
<ref id="bibr29-1352458511431076">
<label>29.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Benedict</surname><given-names>RH</given-names></name>
<name name-style="western"><surname>Duquin</surname><given-names>JA</given-names></name>
<name name-style="western"><surname>Jurgensen</surname><given-names>S</given-names></name>
<etal/>
</person-group>. <article-title>Repeated assessment of neuropsychological deficits in multiple sclerosis using the Symbol Digit Modalities Test and the MS Neuropsychological Screening Questionnaire</article-title>. <source>Mult Scler</source> <year>2008</year>; <volume>14</volume>: <fpage>940</fpage>–<lpage>946</lpage>.</citation>
</ref>
<ref id="bibr30-1352458511431076">
<label>30.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Morrow</surname><given-names>SA</given-names></name>
<name name-style="western"><surname>Drake</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Zivadinov</surname><given-names>R</given-names></name>
<name name-style="western"><surname>Munschauer</surname><given-names>F</given-names></name>
<name name-style="western"><surname>Weinstock-Guttman</surname><given-names>B</given-names></name>
<name name-style="western"><surname>Benedict</surname><given-names>RH</given-names></name>
</person-group>. <article-title>Predicting loss of employment over three years in multiple sclerosis: clinically meaningful cognitive decline</article-title>. <source>The Clinical Neuropsychologist</source> <year>2010</year>; <volume>24</volume>: <fpage>1131</fpage>–<lpage>1145</lpage></citation>
</ref>
<ref id="bibr31-1352458511431076">
<label>31.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Bomboi</surname><given-names>G</given-names></name>
<name name-style="western"><surname>Ikonomidou</surname><given-names>VN</given-names></name>
<name name-style="western"><surname>Pellegrini</surname><given-names>S</given-names></name>
<etal/>
</person-group>. <article-title>Quality and quantity of diffuse and focal white matter disease and cognitive disability of patients with multiple sclerosis</article-title>. <source>J Neuroimag</source> 2011Apr; <volume>21</volume>(<issue>2</issue>): <fpage>e57</fpage>–<lpage>63</lpage>. (<comment>Epub 2011 April</comment>).</citation>
</ref>
<ref id="bibr32-1352458511431076">
<label>32.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Houtchens</surname><given-names>MK</given-names></name>
<name name-style="western"><surname>Benedict</surname><given-names>RH</given-names></name>
<name name-style="western"><surname>Kiliiany</surname><given-names>R</given-names></name>
<etal/>
</person-group>. <article-title>Thalamic atrophy and cognition in multiple sclerosis</article-title>. <source>Neurology</source> <year>2007</year>; <volume>18</volume>: <fpage>1213</fpage>–<lpage>1223</lpage>.</citation>
</ref>
<ref id="bibr33-1352458511431076">
<label>33.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Brochet</surname><given-names>B</given-names></name>
<name name-style="western"><surname>Deloire</surname><given-names>MS</given-names></name>
<name name-style="western"><surname>Bonnet</surname><given-names>M</given-names></name>
<etal/>
</person-group>. <article-title>Should SDMT substitute for PASAT in MSFC? A 5-year longitudinal study</article-title>. <source>Mult Scler</source> <year>2008</year>; <volume>14</volume>: <fpage>1242</fpage>–<lpage>1249</lpage>.</citation>
</ref>
<ref id="bibr34-1352458511431076">
<label>34.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Mike</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Glanz</surname><given-names>BI</given-names></name>
<name name-style="western"><surname>Hildenbrand</surname><given-names>P</given-names></name>
<etal/>
</person-group>. <article-title>Identification and clinical impact of multiple sclerosis cortical lesions as assessed by routine 3T MR imaging</article-title>. <source>AJNR Am J Neuroradiol</source> <year>2011</year>; <volume>32</volume>: <fpage>515</fpage>–<lpage>521</lpage>.</citation>
</ref>
<ref id="bibr35-1352458511431076">
<label>35.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Stankiewicz</surname><given-names>JM</given-names></name>
<name name-style="western"><surname>Glanz</surname><given-names>BI</given-names></name>
<name name-style="western"><surname>Healy</surname><given-names>BC</given-names></name>
<etal/>
</person-group>. <article-title>Brain MRI lesion load at 1.5T and 3T versus clinical status in multiple sclerosis</article-title>. <source>J Neuroimag</source> <year>2011</year> <month>Apr</month>; <volume>21</volume>(<issue>2</issue>): <fpage>e50</fpage>–<lpage>6</lpage>. (<comment>Epub 2011 April</comment>).</citation>
</ref>
<ref id="bibr36-1352458511431076">
<label>36.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Camp</surname><given-names>SJ</given-names></name>
<name name-style="western"><surname>Stevenson</surname><given-names>VL</given-names></name>
<name name-style="western"><surname>Thompson</surname><given-names>AJ</given-names></name>
<etal/>
</person-group>. <article-title>A longitudinal study of cognition in primary progressive multiple sclerosis</article-title>. <source>Brain</source> <year>2005</year>; <volume>128</volume>: <fpage>2891</fpage>–<lpage>2898</lpage>.</citation>
</ref>
<ref id="bibr37-1352458511431076">
<label>37.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Benedict</surname><given-names>RH</given-names></name>
<name name-style="western"><surname>Ramasamy</surname><given-names>D</given-names></name>
<name name-style="western"><surname>Munschauer</surname><given-names>F</given-names></name>
<name name-style="western"><surname>Weinstock-Guttman</surname><given-names>B</given-names></name>
<name name-style="western"><surname>Zivadinov</surname><given-names>R</given-names></name>
</person-group>. <article-title>Memory impairment in multiple sclerosis: correlation with deep grey matter and mesial temporal atrophy</article-title>. <source>J Neurol, Neurosurg Psychiat</source> <year>2009</year>; <volume>80</volume>: <fpage>201</fpage>–<lpage>206</lpage>.</citation>
</ref>
<ref id="bibr38-1352458511431076">
<label>38.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Warlop</surname><given-names>NP</given-names></name>
<name name-style="western"><surname>Achten</surname><given-names>E</given-names></name>
<name name-style="western"><surname>Fieremans</surname><given-names>E</given-names></name>
<name name-style="western"><surname>Debruyne</surname><given-names>J</given-names></name>
<name name-style="western"><surname>Vingerhoets</surname><given-names>G</given-names></name>
</person-group>. <article-title>Transverse diffusivity of cerebral parenchyma predicts visual tracking performance in relapsing–remitting multiple sclerosis</article-title>. <source>Brain and Cognition</source> <year>2009</year>; <volume>71</volume>: <fpage>410</fpage>–<lpage>415</lpage>.</citation>
</ref>
<ref id="bibr39-1352458511431076">
<label>39.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Einarsson</surname><given-names>U</given-names></name>
<name name-style="western"><surname>Gottberg</surname><given-names>K</given-names></name>
<name name-style="western"><surname>von Koch</surname><given-names>L</given-names></name>
<etal/>
</person-group>. <article-title>Cognitive and motor function in people with multiple sclerosis in Stockholm County</article-title>. <source>Mult Scler</source> <year>2006</year>; <volume>12</volume>: <fpage>340</fpage>–<lpage>353</lpage>.</citation>
</ref>
<ref id="bibr40-1352458511431076">
<label>40.</label>
<citation citation-type="book" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Delis</surname><given-names>DC</given-names></name>
<name name-style="western"><surname>Kramer</surname><given-names>JH</given-names></name>
<name name-style="western"><surname>Kaplan</surname><given-names>E</given-names></name>
<name name-style="western"><surname>Ober</surname><given-names>BA</given-names></name>
</person-group>. <source>California Verbal Learning Test</source>, <edition>second edition</edition> (<comment>CVLT-II</comment>). <publisher-loc>San Antonio, TX</publisher-loc>: <publisher-name>Psychological Corporation</publisher-name>; <year>2000</year>.</citation>
</ref>
<ref id="bibr41-1352458511431076">
<label>41.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Stegan</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Stepanov</surname><given-names>I</given-names></name>
<name name-style="western"><surname>Cookfair</surname><given-names>D</given-names></name>
<etal/>
</person-group>. <article-title>Validity of the California Verbal Learning Test-II in multiple sclerosis</article-title>. <source>The Clinical Neuropsychologist</source> <year>2010</year>; <volume>24</volume>: <fpage>189</fpage>–<lpage>202</lpage>.</citation>
</ref>
<ref id="bibr42-1352458511431076">
<label>42.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Fink</surname><given-names>F</given-names></name>
<name name-style="western"><surname>Eling</surname><given-names>P</given-names></name>
<name name-style="western"><surname>Rischkau</surname><given-names>E</given-names></name>
<etal/>
</person-group>. <article-title>The association between California Verbal Learning Test performance and fibre impairment in multiple sclerosis: evidence from diffusion tensor imaging</article-title>. <source>Mult Scler</source> <year>2010</year>; <volume>16</volume>: <fpage>332</fpage>–<lpage>341</lpage>.</citation>
</ref>
<ref id="bibr43-1352458511431076">
<label>43.</label>
<citation citation-type="book" xlink:type="simple">
<person-group person-group-type="editor">
<name name-style="western"><surname>Sartori</surname><given-names>E</given-names></name>
<name name-style="western"><surname>Edan</surname><given-names>G</given-names></name>
</person-group>. <article-title>Assessment of cognitive dysfunction in multiple sclerosis</article-title>. <source>J Neurol Sci</source> <year>2006</year>; <volume>245</volume>: <fpage>169</fpage>–<lpage>175</lpage>.</citation>
</ref>
<ref id="bibr44-1352458511431076">
<label>44.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Benedict</surname><given-names>RH</given-names></name>
<name name-style="western"><surname>Bakshi</surname><given-names>R</given-names></name>
<name name-style="western"><surname>Simon</surname><given-names>JH</given-names></name>
<name name-style="western"><surname>Priore</surname><given-names>R</given-names></name>
<name name-style="western"><surname>Miller</surname><given-names>C</given-names></name>
<name name-style="western"><surname>Munschauer</surname><given-names>F</given-names></name>
</person-group>. <article-title>Frontal cortex atrophy predicts cognitive impairment in multiple sclerosis</article-title>. <source>J Neuropsych Clin Neurosci</source> <year>2002</year>; <volume>14</volume>: <fpage>44</fpage>–<lpage>51</lpage>.</citation>
</ref>
<ref id="bibr45-1352458511431076">
<label>45.</label>
<citation citation-type="book" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Benedict</surname><given-names>RHB</given-names></name>
</person-group>. <source>The Brief Visuospatial Memory Test Revised (BVMT-R)</source>. <publisher-loc>Lutz, FL</publisher-loc>: <publisher-name>Psychosocial Assessment Resources Inc</publisher-name>; <year>1997</year>.</citation>
</ref>
<ref id="bibr46-1352458511431076">
<label>46.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Rozewicz</surname><given-names>L</given-names></name>
<name name-style="western"><surname>Langdon</surname><given-names>DW</given-names></name>
<name name-style="western"><surname>Davie</surname><given-names>CA</given-names></name>
<name name-style="western"><surname>Ron</surname><given-names>MA</given-names></name>
<name name-style="western"><surname>Thompson</surname><given-names>AJ</given-names></name>
</person-group>. <article-title>Reversible focal cognitive impairment in multiple sclerosis</article-title>. <source>Cognitive Neuropsychiatry</source> <year>1996</year>; <volume>1</volume>: <fpage>17</fpage>–<lpage>25</lpage>.</citation>
</ref>
<ref id="bibr47-1352458511431076">
<label>47.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Brunner</surname><given-names>R</given-names></name>
<name name-style="western"><surname>Schaefer</surname><given-names>D</given-names></name>
<name name-style="western"><surname>Hess</surname><given-names>K</given-names></name>
<name name-style="western"><surname>Parzer</surname><given-names>P</given-names></name>
<name name-style="western"><surname>Resch</surname><given-names>F</given-names></name>
<name name-style="western"><surname>Schwab</surname><given-names>S</given-names></name>
</person-group>. <article-title>Effect of high-dose cortisol on memory functions</article-title>. <source>Ann NY Acad Sci</source> <year>2006</year>; <volume>1071</volume>: <fpage>434</fpage>–<lpage>437</lpage>.</citation>
</ref>
<ref id="bibr48-1352458511431076">
<label>48.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Smith</surname><given-names>MM</given-names></name>
<name name-style="western"><surname>Arnett</surname><given-names>PA</given-names></name>
</person-group>. <article-title>Dysarthria predicts poorer performance on cognitive tasks requiring a speeded oral response in an MS population</article-title>. <source>J Clin Exp Neuropsychol</source> <year>2007</year>; <volume>29</volume>: <fpage>804</fpage>–<lpage>812</lpage>.</citation>
</ref>
<ref id="bibr49-1352458511431076">
<label>49.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Bruce</surname><given-names>JM</given-names></name>
<name name-style="western"><surname>Bruce</surname><given-names>AS</given-names></name>
<name name-style="western"><surname>Arnett</surname><given-names>PA</given-names></name>
</person-group>. <article-title>Mild visual acuity disturbances are associated with performance on tests of complex visual attention in MS</article-title>. <source>J Int Neuropsychol Soc</source> <year>2007</year>; <volume>13</volume>: <fpage>544</fpage>–<lpage>548</lpage>.</citation>
</ref>
<ref id="bibr50-1352458511431076">
<label>50.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Boringa</surname><given-names>JB</given-names></name>
<name name-style="western"><surname>Lazeron</surname><given-names>RH</given-names></name>
<name name-style="western"><surname>Reuling</surname><given-names>IE</given-names></name>
<etal/>
</person-group>. <article-title>The brief repeatable battery of neuropsychological tests: normative values allow application in multiple sclerosis clinical practice</article-title>. <source>Mult Scler</source> <year>2001</year>; <volume>7</volume>: <fpage>263</fpage>–<lpage>267</lpage>.</citation>
</ref>
<ref id="bibr51-1352458511431076">
<label>51.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Amato</surname><given-names>MP</given-names></name>
<name name-style="western"><surname>Portaccio</surname><given-names>E</given-names></name>
<name name-style="western"><surname>Goretti</surname><given-names>B</given-names></name>
<etal/>
</person-group>. <article-title>The Rao’s Brief Repeatable Battery and Stroop Test: normative values with age, education and gender corrections in an Italian population</article-title>. <source>Mult Scler</source> <year>2006</year>; <volume>12</volume>: <fpage>787</fpage>–<lpage>793</lpage>.</citation>
</ref>
<ref id="bibr52-1352458511431076">
<label>52.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Oken</surname><given-names>BS</given-names></name>
<name name-style="western"><surname>Flegal</surname><given-names>K</given-names></name>
<name name-style="western"><surname>Zajdel</surname><given-names>D</given-names></name>
<etal/>
</person-group> <article-title>Cognition and fatigue in multiple sclerosis: Potential effects of medications with central nervous system activity</article-title>. <source>J Rehab Res Dev</source> <year>2006</year>; <volume>43</volume>: <fpage>83</fpage>–<lpage>90</lpage>.</citation>
</ref>
<ref id="bibr53-1352458511431076">
<label>53.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Hindmarch</surname><given-names>I</given-names></name>
</person-group>. <article-title>Cognitive toxicity of pharmacotherapeutic agents used in social anxiety disorder</article-title>. <source>Int J Clin Prac</source> <year>2009</year>; <volume>63</volume>: <fpage>1085</fpage>–<lpage>1094</lpage>.</citation>
</ref>
<ref id="bibr54-1352458511431076">
<label>54.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Dario</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Pisani</surname><given-names>R</given-names></name>
<name name-style="western"><surname>Sangiorgi</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Pessina</surname><given-names>F</given-names></name>
<name name-style="western"><surname>Tomei</surname><given-names>G</given-names></name>
</person-group>. <article-title>Relationship between intrathecal baclofen and the central nervous system</article-title>. <source>Acta Neurochir</source> <year>2007</year>; <volume>97</volume>(<supplement>Suppl.</supplement>): <fpage>461</fpage>–<lpage>464</lpage>.</citation>
</ref>
<ref id="bibr55-1352458511431076">
<label>55.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Stephen</surname><given-names>LJ</given-names></name>
<name name-style="western"><surname>Brodie</surname><given-names>MJ</given-names></name>
</person-group>. <article-title>Pharmacotherapy of epilepsy: newly approved and developmental agents</article-title>. <source>CNS Drugs</source> <year>2011</year>; <volume>25</volume>: <fpage>89</fpage>–<lpage>107</lpage>.</citation>
</ref>
<ref id="bibr56-1352458511431076">
<label>56.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Ghaffar</surname><given-names>O</given-names></name>
<name name-style="western"><surname>Feinstein</surname><given-names>A</given-names></name>
</person-group>. <article-title>Multiple sclerosis and cannabis: a cognitive and psychiatric study</article-title>. <source>Neurology</source> <year>2008</year>; <volume>71</volume>: <fpage>164</fpage>–<lpage>169</lpage>.</citation>
</ref>
<ref id="bibr57-1352458511431076">
<label>57.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Rabinowitz</surname><given-names>AR</given-names></name>
<name name-style="western"><surname>Arnett</surname><given-names>PA</given-names></name>
</person-group>. <article-title>A longitudinal analysis of cognitive dysfunction, coping, and depression in multiple sclerosis</article-title>. <source>Neuropsychology</source> <year>2009</year>; <volume>23</volume>: <fpage>581</fpage>–<lpage>591</lpage>.</citation>
</ref>
<ref id="bibr58-1352458511431076">
<label>58.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Benedict</surname><given-names>RH</given-names></name>
<name name-style="western"><surname>Cox</surname><given-names>D</given-names></name>
<name name-style="western"><surname>Thompson</surname><given-names>LL</given-names></name>
<name name-style="western"><surname>Foley</surname><given-names>F</given-names></name>
<name name-style="western"><surname>Weinstock-Guttman</surname><given-names>B</given-names></name>
<name name-style="western"><surname>Munschauer</surname><given-names>F</given-names></name>
</person-group>. <article-title>Reliable screening for neuropsychological impairment in multiple sclerosis</article-title>. <source>Mult Scler</source> <year>2004</year>; <volume>10</volume>: <fpage>675</fpage>–<lpage>678</lpage>.</citation>
</ref>
<ref id="bibr59-1352458511431076">
<label>59.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Krupp</surname><given-names>LB</given-names></name>
<name name-style="western"><surname>Serafin</surname><given-names>DJ</given-names></name>
<name name-style="western"><surname>Christodoulou</surname><given-names>C</given-names></name>
</person-group>. <article-title>Multiple sclerosis-associated fatigue</article-title>. <source>Expert Rev Neurother</source> <year>2010</year>; <volume>10</volume>: <fpage>1437</fpage>–<lpage>1447</lpage>.</citation>
</ref>
<ref id="bibr60-1352458511431076">
<label>60.</label>
<citation citation-type="journal" xlink:type="simple">
<person-group person-group-type="author">
<name name-style="western"><surname>Ebers</surname><given-names>GC</given-names></name>
<name name-style="western"><surname>Reder</surname><given-names>AT</given-names></name>
<name name-style="western"><surname>Traboulsee</surname><given-names>A</given-names></name>
<etal/>
</person-group>. <article-title>Long-term follow-up of the original interferon-beta 1b trial in multiple scelrosis: design and lessons from a 16-year observational study</article-title>. <source>Clin Therap</source> <year>2009</year>; <volume>31</volume>: <fpage>1724</fpage>–<lpage>1736</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>